The anti-PDx class of drugs represents a paradigm shift in terms of how cancer patients are managed, and it is a category supported by unprecedented levels of R&D investment by industry. While analyst forecasts for these drugs already sit at impressively high levels, there are still additional sources of upside to contemplate. The three that we commonly cite include: (1) moving anti-PDx therapies upstream in the management of cancer, from the metastatic to the “adjuvant” setting; (2) figuring out which combinations, with either existing cancer medicines or new ones in development, may make the anti-PDx’s even more effective; and (3) the potential under-modeling of the ex-US anti-PDx opportunity.
Search Coverage List, Models & Reports
Search Results1-10 out of 39
Our slides from the Wolfe Research Healthcare Biweekly Webcast covering POSEIDON and NEPTUNE, AZN’s off-the-radar 1L lung trials.
Bristol-Myers Squibb reported 1Q19 financial results this morning (4/25/19). This report summarizes key takeaways from the conference call that go above and beyond information provided in the press release.
Bristol-Myers Squibb (BMY) announced 1Q19 financial results this morning (4/25/19)—higher on revenues, but only slightly higher on EPS. Revenues of $5.92B vs. our $5.61B and consensus $5.75B. EPS of $1.10 vs. our $1.08 and consensus of $1.09.
The Q1 2019 earnings season for our ten covered US/EU pharmaceutical companies is about to begin. It starts Wednesday, April 17th with Roche and ends Wednesday, May 1st with GlaxoSmithKline. This report contains our updated forecasts (out to 2028) and perspectives.
We track Emerging Markets growth rates for our covered companies. It has accelerated consistently since mid-2016; in Q4 2018 it was 9.3% y/y. From Q1 2012 to Q3 2018, y/y growth has been: 6.4% à10.3% à9.1% à9.5% à7.4% à6.1% à3.9% à9.5% à6.4% à8.3% à10.9% à8.0% à7.5% à4.7% à3.6% à3.2% à4.4% à1.8% à3.6% à3.3% à5.8% à6.1% à7.4% à7.5% à9.1% à9.5% à11.6% à 9.3% (Exhibit 1).
Our slides from the Wolfe Research Healthcare Biweekly Webcast, recapping our thoughts on: (1) MRK vs. PFE’s race for a next generation pneumococcal vaccine; and (2) key takeaways from our BMY “Pipelines Unplugged” conference call.
This 80p report covers the bull/bear case, current controversies, relative growth prospects and more for our 10 US & EU global pharmaceutical companies.
On April 3rd, we held the second of our "Pipelines Unplugged" conference calls (where we interview R&D management in a fireside chat format) with Bristol-Myers Squibb.
- 1 of 4
- next →